5323002022-07-012022-09-305323002022-09-305323002022-03-315323002022-04-012022-09-305323002022-07-012022-09-30in-bse-fin:OtherExpenses1Member5323002022-04-012022-09-30in-bse-fin:OtherExpenses1Member5323002022-07-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15323002022-04-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15323002022-07-012022-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15323002022-04-012022-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532300WOCKPHARMANAINE049B01025Wockhardt LimitedEquity2022-04-012023-03-312022-11-042022-10-28INRCroresHalf yearlySingle segmentPharmaceuticals2022-11-0411:30:002022-11-0413:45:00trueCash Flow IndirectNot applicable2022-07-012022-09-30UnauditedConsolidated6790000000570000000736000000010800000001360000000140000000163000000070000000065000000021500000007710000000-350000000-1950000000-230000000040000000-270000000-2300000000-20700000000000-2070000000-650000000-2720000000-1890000000-180000000-2630000000-900000007200000005-13.15-13.1500-13.15-13.15000Notes To consolidated Results:- <BR> <BR> 1. For Notes to Consolidated Results please refer the notes from the Statement of Consolidated Audited Results for the quarter and half year ended September 30, 2022 as attached which is submitted under Outcome of Board Meeting today. <BR> <BR> 2. EPS for the quarter and half year ended September 30, 2022 is not annualised. <BR> <BR> Notes to Cash Flow Statements <BR> <BR> 1. For Notes to Cash flow statement, please refer Audited Results for the quarter and half year ended September 30, 2022 as attached which is submitted under Outcome of Board Meeting today. <BR> <BR> 2.Proceeds from issuance of shares includes transaction cost relating to Right Issue of Rs. 1 Crore. <BR> <BR> 3. Proceeds from borrowing includes proceeds from short term borrowings Rs.66 crore and loan from Related Parties Rs. 187 crore. <BR> <BR> 4. Repayment from borrowing includes repayment of long term borrowings Rs.170 crore and repayment of loan taken from Related Parties Rs. 68 crore. <BR> <BR> 5. Aggregated/segregated in accordance with the prescribed format and to the extent is the requirement of the accounting standard. <BR> <BR> Please also, additionally refer to the Statement of Consolidated Unaudited Results for the quarter and half year ended September 30, 2022 as attached to the Outcome of Board Meeting.2022-04-012022-09-30UnauditedConsolidated1274000000011400000001388000000024800000002510000000-140000000343000000014300000001290000000419000000015190000000-1310000000-1950000000-326000000080000000-520000000-4400000000-28200000000000-2820000000-850000000-3670000000-2560000000-260000000-3570000000-1000000007200000005-17.8-17.800-17.8-17.8000Other expenses2150000000Other expenses4190000000223500000003950000000849000000089000000010930000000006000000006000000006340000000217000000055720000000748000000008160000000187000000034000000001300000001050000000032000000002118000000014400000007834000000072000000034220000000349400000003430000000383700000002430000000365000000060800000003400000002900000008000000007510000000161300000007400000000692000000030450000000141000000043000000017000000032460000000039970000000783400000001. Property, Plant and Equipment Includes Right of use assets amounting to Rs. 529.00 crore <BR> <BR> 2. Other non-current assets includes Non-current tax assets (net) amounting to Rs. 113.00 crore <BR> <BR> 3. Other non-current financial liabilities consists Lease liabilities amounting to Rs.245.00 crore <BR> <BR> 4. Other current financial liabilities include Lease liabilities amounting to Rs.70.00 crore. <BR> <BR> 5. Non-current assets classified as held for sale represents Assets classified as held for sale. <BR> <BR> Please also, additionally refer to the Statement of Consolidated Unaudited Results for the quarter and half year ended September 30, 2022 as attached to the Outcome of Board Meeting.1430000000210000000163000000000-250000000000001800000000129000000012300000000000-1060000000030000000100000000000-690000000039500000006900000000008000000006100000000000000009000000000000100000000000000000000010000000050000000-103000000000-10000000000002530000000238000000035000000000120000000000-1410000000-18300000000-183000000037000000001870000000Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) (Continuing operations)-50000000-50000000Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) (Continuing operations)-110000000-110000000-10000000-20000000Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations)-610000000-610000000Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations)-760000000-76000000000